Pianzaihuang's Earnings Below Expectations, Yet Goldman Sachs Remains Bullish

Overview

Following Pianzaihuang’s FY25 annual report and 1Q26 quarterly report, Goldman Sachs commented on the below-expectations performance: FY25 revenue reached RMB 9 billion, net profit RMB 2.16 billion, down 17% and 27% YoY respectively, both missing forecasts; 1Q26 revenue was RMB 2.74 billion, net profit RMB 743 million, continuing to drop 13% and 26% YoY. The report lowered its revenue and net profit forecasts for 2026-28 by an average of 20%-40%, reducing the target price from RMB 230 to RMB 200, yet maintaining a “buy” rating, believing that end-demand has turned a corner and valuation has room for recovery.

Core views

Demand Side: The report attributes the earnings decline primarily to reduced willingness to consume high-end traditional Chinese medicine, putting pressure on sales of the company’s core products. Supply Side: Earlier channel inventories were relatively high, but March end-market sales surged 36% YoY, showing consecutive two-month improvement month-on-month; inventory pressure has significantly eased, and the company’s shipment growth is expected to turn positive starting from Q226. Profitability and Valuation: Despite lowering profit forecasts, Pianzaihuang still boasts strong brand moats, with gross and EBIT margins consistently around 40% and 30%; current valuation is notably below the five-year average, with a 50x 2026E PE at a historic low, providing a solid foundation for valuation recovery. Catalysts: Recovering end-demand, completed inventory destocking, and turning positive sales growth will serve as catalysts for the stock price.

Analysis framework

Goldman Sachs adopted a method combining earnings tracking with terminal data validation: first comparing reported figures with its own forecasts, then monitoring terminal sales through third-party pharmacy data, and using inventory cycles to identify turning points. At the valuation level, it anchored the target price at a 50x 2026E PE, referencing historical valuation ranges and profit recovery expectations.

Methodology notes

• Valuation MethodPE Valuation

  Using a 50x 2026 expected price-to-earnings ratio as the core anchor for the target price

  Goldman Sachs derives the target price by multiplying next year’s earnings by the target PE multiple; the 50x corresponds to Pianzaihuang’s brand premium and profit recovery expectations

• Industry/Industrial Analysis FrameworkVolume-price decomposition

  Breaking down revenue changes into contributions from volume and price, and paying attention to the lagged impact of channel inventory on sales

  The report predicts when the company’s shipments will turn positive based on changes in terminal sales and channel inventory levels

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pianzaihuang (600436.SS)

  Core covered asset, leading brand in traditional Chinese medicine, short-term performance under pressure but long-term moat remains solid

  Strengths

  Strong brand power, high gross margin on core products, channel inventory turning point becoming evident

  Weaknesses

  Weak high-end consumption leading to declining sales, short-term earnings below expectations

  Risks

  Brand damage, lower-than-expected returns on new products, sales falling short of expectations after price hikes, continued weak consumer spending, rising costs, ESG risks, and uncertainties from the CDl investigation

Key data

• FY25 RevenueRMB 9.001 billionDown 17% YoY, below the forecasted RMB 9.636 billion
• FY25 Net ProfitRMB 2.159 billionDown 27% YoY, below the forecasted RMB 2.564 billion
• 1Q26 RevenueRMB 2.741 billionDown 13% YoY, below the forecasted RMB 3.114 billion
• 1Q26 Net ProfitRMB 743 millionDown 26% YoY, below the forecasted RMB 1.049 billion
• March Terminal Sales Growth+36%Improving month-on-month for two consecutive months
• 2026E EPSRMB 3.88Lowered by 22.7% from the original forecast
• Target PE50xCorresponding to a target price of RMB 200
• Current Market CapRMB 86.6 billionCorresponding to a 2026E PE of 37x

Impact & implications

The report believes that although short-term performance is under pressure, positive signals have emerged from recovering end-demand and inventory destocking, suggesting that the bottom of profitability may have passed. The valuation below historical averages provides a safety cushion for the stock price; once sales growth turns positive, both valuation and profitability could see a double boost. Investors can pay close attention to the turning point confirmed by sales data starting from Q226.

Risks

• Brand reputation affected by unexpected events
• New product and investment returns below expectations
• Sales recovery slower than expected after price hikes
• Continued slump in high-end discretionary consumption
• Additional shocks from channel adjustments
• Rising raw material costs and supply security
• ESG-related risks
• Uncertainty over the progress of the CDl investigation

What to watch

• Whether the company’s sales growth will turn positive as scheduled starting from Q226
• Continuous tracking of terminal pharmacy sales data
• Changes in channel inventory levels
• Subsequent pricing strategies and market reactions